type 2 diabetes with hypercholesterolemia
Conditions
Interventions
Ezetimibe (10mg) daily, for 4 months
Sponsors
Kobe University Graduate School of Medicine, Division of Diabetes, Metabolism and Endocrinology
Rokko Island Hspital, Konan Hospital, Shin-Suma Hospital, Obara Hospital, Sugano Clinic, Ooshiro Clinic, Amano Clinic, Osaka Koseinenkin Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients who meet all of the following criteria: 1) Patients with type 2 diabetes over 20 yeras old 2)Patients who have been treated with statins for more than 3 months 3)Patients whose serum LDL cholesterol levels do not reach the control target values of Japan Atherosclerosis Society Guideline 2007.
Exclusion criteria
Exclusion criteria: 1)During pregnancy or lactation 2)Patients who had allergy to ezetimibe 3)Serious liver or renal diseases 4)Acute or chronic inflammatory diseases 5)Other conditions precluding participation as judged by the investigator
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change of the serum levels of RLP- Cholesterol (4 months after initiaion of therapy) | — |
Secondary
| Measure | Time frame |
|---|---|
| Change of the serum levels of the following serum inflammatory markers and lipids(4 months after initiaion of therapy) 1)hsCRP, 2)IL-6, 3)IL-18, 4)apoB48, 5)total cholesterol, 6)LDL cholesterol, 7)HDL cholesterol, 8)triglyceride, 9)adiponectin, 10)TNFa, 11)insulin | — |
Countries
Japan
Contacts
Public ContactWataru Ogawa
Kobe University Graduate School of Medicine Division of Diabetes, Metabolism and Endocrinology
Outcome results
None listed